Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $76.50 Average Target Price from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned an average recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $76.50.

Several brokerages have recently commented on GPCR. HC Wainwright reduced their target price on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a report on Monday, May 12th. Citigroup began coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a “buy” rating and a $60.00 price objective for the company. Finally, William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock.

Institutional Trading of Structure Therapeutics

Hedge funds have recently modified their holdings of the stock. Deep Track Capital LP lifted its stake in shares of Structure Therapeutics by 129.4% in the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock valued at $75,936,000 after purchasing an additional 1,579,492 shares during the period. Vestal Point Capital LP increased its stake in shares of Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after acquiring an additional 575,000 shares during the last quarter. Boxer Capital Management LLC acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at approximately $13,560,000. Marshall Wace LLP boosted its stake in Structure Therapeutics by 339.6% during the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company’s stock worth $15,817,000 after acquiring an additional 450,531 shares during the last quarter. Finally, Foresite Capital Management VI LLC acquired a new position in Structure Therapeutics during the fourth quarter valued at approximately $11,390,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR opened at $21.83 on Friday. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $54.08. The business’s fifty day moving average price is $22.18 and its two-hundred day moving average price is $24.86. The firm has a market capitalization of $1.25 billion, a PE ratio of -29.50 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Equities research analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.